Limits...
Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis.

Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, Sousa AL, Pereira VB, de Azevedo M, Moraes K, Cara DC, LeBlanc JG, Azevedo V, Faria AM, Miyoshi A - Gut Pathog (2014)

Bottom Line: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect.This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue.Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

View Article: PubMed Central - HTML - PubMed

Affiliation: Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627 - 31270-901 Belo Horizonte, MG, Brazil.

ABSTRACT

Background: Many probiotic bacteria have been described as promising tools for the treatment and prevention of inflammatory bowel diseases (IBDs). Most of these bacteria are lactic acid bacteria, which are part of the healthy human microbiota. However, little is known about the effects of transient bacteria present in normal diets, including Lactococcus lactis.

Methods: In the present study, we analysed the immunomodulatory effects of three L. lactis strains in vitro using intestinal epithelial cells. L. lactis NCDO 2118 was administered for 4 days to C57BL/6 mice during the remission period of colitis induced by dextran sodium sulphate (DSS).

Results: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect. Oral treatment using L. lactis NCDO 2118 resulted in a milder form of recurrent colitis than that observed in control diseased mice. This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue. Mice fed L. lactis NCDO 2118 had an increased number of regulatory CD4(+) T cells (Tregs) bearing surface TGF-β in its latent form (Latency-associated peptide-LAP) in the mesenteric lymph nodes and spleen.

Conclusions: Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

No MeSH data available.


Related in: MedlinePlus

Oral administration of L. lactis NCDO 2118 did not alter secretory IgA production. (A) Intestinal faeces were collected and total sIgA was measured by ELISA in mice from control, DSS and DSS + NCDO2118 groups. (B) Intestinal faeces from healthy mice were collected after 2, 3 or 4 days of L. lactis administration, and total sIgA was measured by ELISA. Bars represent the mean ± MSE of 5 mice per group. **, p < 0.01.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4126083&req=5

Figure 4: Oral administration of L. lactis NCDO 2118 did not alter secretory IgA production. (A) Intestinal faeces were collected and total sIgA was measured by ELISA in mice from control, DSS and DSS + NCDO2118 groups. (B) Intestinal faeces from healthy mice were collected after 2, 3 or 4 days of L. lactis administration, and total sIgA was measured by ELISA. Bars represent the mean ± MSE of 5 mice per group. **, p < 0.01.

Mentions: Secretory IgA was evaluated in mouse faeces at days 14 and 21. The levels of sIgA were increased only after the second colitis cycle. Oral administration of L. lactis NCDO 2118 maintained sIgA production at intermediate levels (Figure 4A). To verify whether L. lactis was able to modify the sIgA levels in a physiological scenario, we measured sIgA levels after 2, 3 or 4 days of oral administration of L. lactis. L. lactis NCDO 2118 did not alter sIgA production (Figure 4B), discarding the possibility that IgA modulation might be a regulatory mechanism mediated by L. lactis.


Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis.

Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, Sousa AL, Pereira VB, de Azevedo M, Moraes K, Cara DC, LeBlanc JG, Azevedo V, Faria AM, Miyoshi A - Gut Pathog (2014)

Oral administration of L. lactis NCDO 2118 did not alter secretory IgA production. (A) Intestinal faeces were collected and total sIgA was measured by ELISA in mice from control, DSS and DSS + NCDO2118 groups. (B) Intestinal faeces from healthy mice were collected after 2, 3 or 4 days of L. lactis administration, and total sIgA was measured by ELISA. Bars represent the mean ± MSE of 5 mice per group. **, p < 0.01.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4126083&req=5

Figure 4: Oral administration of L. lactis NCDO 2118 did not alter secretory IgA production. (A) Intestinal faeces were collected and total sIgA was measured by ELISA in mice from control, DSS and DSS + NCDO2118 groups. (B) Intestinal faeces from healthy mice were collected after 2, 3 or 4 days of L. lactis administration, and total sIgA was measured by ELISA. Bars represent the mean ± MSE of 5 mice per group. **, p < 0.01.
Mentions: Secretory IgA was evaluated in mouse faeces at days 14 and 21. The levels of sIgA were increased only after the second colitis cycle. Oral administration of L. lactis NCDO 2118 maintained sIgA production at intermediate levels (Figure 4A). To verify whether L. lactis was able to modify the sIgA levels in a physiological scenario, we measured sIgA levels after 2, 3 or 4 days of oral administration of L. lactis. L. lactis NCDO 2118 did not alter sIgA production (Figure 4B), discarding the possibility that IgA modulation might be a regulatory mechanism mediated by L. lactis.

Bottom Line: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect.This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue.Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

View Article: PubMed Central - HTML - PubMed

Affiliation: Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627 - 31270-901 Belo Horizonte, MG, Brazil.

ABSTRACT

Background: Many probiotic bacteria have been described as promising tools for the treatment and prevention of inflammatory bowel diseases (IBDs). Most of these bacteria are lactic acid bacteria, which are part of the healthy human microbiota. However, little is known about the effects of transient bacteria present in normal diets, including Lactococcus lactis.

Methods: In the present study, we analysed the immunomodulatory effects of three L. lactis strains in vitro using intestinal epithelial cells. L. lactis NCDO 2118 was administered for 4 days to C57BL/6 mice during the remission period of colitis induced by dextran sodium sulphate (DSS).

Results: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect. Oral treatment using L. lactis NCDO 2118 resulted in a milder form of recurrent colitis than that observed in control diseased mice. This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue. Mice fed L. lactis NCDO 2118 had an increased number of regulatory CD4(+) T cells (Tregs) bearing surface TGF-β in its latent form (Latency-associated peptide-LAP) in the mesenteric lymph nodes and spleen.

Conclusions: Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

No MeSH data available.


Related in: MedlinePlus